With a rapid increase in the prevalence of diabetes mellitus (DM), projected to affect more than 600 million people by 2040, ocular complications have become a leading cause of blindness worldwide.
1,2 In addition to abnormalities of the retina (e.g., diabetic retinopathy)
3 and the lens (e.g., cataract),
4 up to 70% of people with diabetes also experience corneal problems, including keratopathy and neuropathy.
5,6 Corneal abnormalities include alterations in the epithelial basement membrane,
7 fewer hemidesmosomes,
8 the deposition of advanced glycation end products,
7,9 and a decrease in the density of corneal sensory nerve fibers and endings.
10 Hyperglycemia significantly alters the structure and function of corneal epithelial cells (CECs), resulting in basal cell degeneration,
11 decreased cell proliferation,
12,13 superficial punctate keratitis,
14 the breakdown of barrier function, fragility,
15,16 recurrent erosions, and persistent epithelial defects,
17 depending on the duration of DM and on the serum concentration of glycated hemoglobin HbA1c.
18 The epithelial abnormalities, termed keratopathy/epitheliopathy, are likely the result of these pathological changes and are resistant to conventional treatment regimens.
19 Hence, a better understanding of the pathogenesis of diabetic keratopathy should lead to better management of the disease.